- Home
- TERN
as 07-26-2024 4:00pm EST
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 602.1M | IPO Year: | 2021 |
| Target Price: | $14.50 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.26 - $10.03 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 29.91% |
Stock Insider Trading Activity of Terns Pharmaceuticals Inc. (TERN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 623 | $6,230.00 | 755,635 | SEC Form 4 |
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 556 | $5,560.00 | 1,967,924 | SEC Form 4 |
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 4,009 | $40,090.00 | 4,839,412 | SEC Form 4 |
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 6,142 | $61,420.00 | 756,258 | SEC Form 4 |
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 5,401 | $54,010.00 | 1,968,480 | SEC Form 4 |
| GORDON CARL L | TERN | Director10% Owner | Jul 15 '24 | Sell | $10.00 | 39,433 | $394,330.00 | 4,843,421 | SEC Form 4 |
| Yoon Seokho Bryan | TERN | COO and General Counsel | May 31 '24 | Buy | $4.44 | 4,791 | $21,272.04 | 91,940 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.99 | 136,255 | $952,422.45 | 4,203,957 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.99 | 39,411 | $275,482.89 | 1,997,146 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.99 | 5,451 | $38,102.49 | 275,772 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.65 | 76,346 | $507,700.90 | 4,127,611 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.65 | 22,084 | $146,858.60 | 1,975,062 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.65 | 3,050 | $20,282.50 | 272,722 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.20 | 103,870 | $643,994.00 | 4,023,741 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.20 | 30,047 | $186,291.40 | 1,945,015 | SEC Form 4 |
| Vivo Opportunity, LLC | TERN | 10% Owner | Apr 1 '24 | Sell | $6.20 | 4,149 | $25,723.80 | 268,573 | SEC Form 4 |
| Yoon Seokho Bryan | TERN | COO and General Counsel | Nov 30 '23 | Buy | $3.78 | 743 | $2,808.54 | 18,399 | SEC Form 4 |
| Vignola Mark J. | TERN | Chief Financial Officer | Nov 30 '23 | Buy | $3.78 | 743 | $2,808.54 | 18,399 | SEC Form 4 |
Latest Terns Pharmaceuticals Inc. News
TERN Breaking Stock News: Dive into TERN Ticker-Specific Updates for Smart Investing
Motley Fool
6 days ago
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
GlobeNewswire
a month ago
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare TERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TERN Terns Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.